RAPT Therapeutics/RAPT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About RAPT Therapeutics

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.

Ticker

RAPT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Brian Wong

Employees

126

Headquarters

South san francisco, United States
Website
rapt.com

RAPT Metrics

BasicAdvanced
$140M
Market cap
-
P/E ratio
-$3.07
EPS
0.26
Beta
-
Dividend rate
$140M
0.25819
$27.35
$3.88
947K
7.009
-58.42%
-67.21%
-65.33%
1.067
1.067
-100.00%
-15.76%

What the Analysts think about RAPT

Analyst Ratings

Majority rating from 11 analysts.
Hold

RAPT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$31M
-0.97%
Profit margin
0.00%
NaN%

RAPT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.26%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.66
-$0.82
-$0.80
-$0.79
-
Expected
-$0.78
-$0.75
-$0.86
-$0.81
-$0.71
Surprise
-15.57%
8.86%
-6.85%
-2.26%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for RAPT Therapeutics stock?

RAPT Therapeutics (RAPT) has a market cap of $140M as of June 19, 2024.

What is the P/E ratio for RAPT Therapeutics stock?

The price to earnings (P/E) ratio for RAPT Therapeutics (RAPT) stock is 0 as of June 19, 2024.

Does RAPT Therapeutics stock pay dividends?

No, RAPT Therapeutics (RAPT) stock does not pay dividends to its shareholders as of June 19, 2024.

When is the next RAPT Therapeutics dividend payment date?

RAPT Therapeutics (RAPT) stock does not pay dividends to its shareholders.

What is the beta indicator for RAPT Therapeutics?

RAPT Therapeutics (RAPT) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the RAPT Therapeutics stock price target?

The target price for RAPT Therapeutics (RAPT) stock is $14.83, which is NaN% below the current price of $. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell RAPT Therapeutics stock

Buy or sell RAPT Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing